Maintenance of CD8+ T-Cell Memory Following Infection with Recombinant Sindbis and Vaccinia Viruses

Villacres, Maria C.; Zuo, Jun; Bergmann, Cornelia C.

doi:10.1006/viro.2000.0255

Cited by 17 publications

(19 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Murine models to predict human cytomegalovirus (CMV) vaccine immunogenicity are available to detect the presence of a specific immune response, such as cytolytic T-lymphocyte (CTL) function (2,5,28), CD4…”

mentioning

confidence: 99%

Use of Transgenic HLA A*0201/Kb and HHD II Mice To Evaluate Frequency of Cytomegalovirus IE1-Derived Peptide Usage in Eliciting Human CD8 Cytokine Response

Gallez-Hawkins

Villacres

et al. 2003

J Virol

Self Cite

View full text Add to dashboard Cite

Unlike the pp65 protein of human cytomegalovirus (CMV), which has an immunodominant peptide, pp65 [495][496][497][498][499][500][501][502][503] , recognized by human CD8؉ cells in the context of HLA A‫,1020ء‬ the fine peptide specificity for CMV IE1 has shown no such immunodominance. With the use of transgenic HLA A‫/1020ء‬Kb and HHD II mice, a selected pool of IE1 peptides, including IE1 p256-264 , IE1 p297-304 , and IE1 p316-324 , were shown to stimulate cytolytic T-lymphocyte lysis in the context of HLA A‫.1020ء‬ Based on an intracellular gamma interferon response, IE1 p297-304 , a previously unrecognized CD8 epitope, triggered a prominent response to CMV IE1 in HLA A‫1020ء‬ subjects.Murine models to predict human cytomegalovirus (CMV) vaccine immunogenicity are available to detect the presence of a specific immune response, such as cytolytic T-lymphocyte (CTL) function (2, 5, 28), CD4ϩ gamma interferon (IFN-␥) helper response (15, 22), or antibody response to specific CMV proteins (18,20,21). Of interest is the use of the transgenic A2Kb mouse containing the human HLA A‫1020ء‬with the murine ␣3 chain (Kb) (9,19,29). The murine model HHD II is also a transgenic HLA A‫1020ء‬ mouse that contains a disrupted murine major histocompatibility complex (MHC) molecule, forcing the mouse to present all its immunological epitopes through the HLA pathway (10). Both have become useful models to investigate peptide recognition of specific proteins that can be extrapolated to human subjects.The immunodominant HLA A‫-1020ء‬restricted peptide (pp65 [495][496][497][498][499][500][501][502][503] ) of CMV pp65 has been well studied (3,6,12,30), whereas there is no immunodominant peptide recognized for the CMV IE1 protein, despite the prevalence of an IE1-specific CTL response (11,14,16,17). Three reports have described the stimulatory effect of peptides IE1 p315-323 , IE1 p316-324 , and IE1 p354-362 from CMV IE1 in the context of HLA A‫1020ء‬ (11, 17, 24) in a cytokine flow cytometry or CTL assay. However, not all CMV-seropositive subjects respond to these peptides (17). This report describes the use of HLA A2 transgenic mice to identify a novel IE1 peptide, IE1-297, that is recognized by murine CTLs as well as human CD8 cells by cytokine flow cytometry.T2 stabilization. T2 cells are defective for endogenous class I presentation, but the presence of peptide binding to the MHC molecule will stabilize its expression on the cell surface. The stabilized MHC molecule can be detected by flow cytometry with a monoclonal antibody to the HLA A‫1020ء‬ molecule (13). The peptide sequences used in this study were collected from two algorithms for HLA peptide predicted motifs: SYFPEITHI (23)

show abstract

mentioning

confidence: 99%

Use of Transgenic HLA A*0201/Kb and HHD II Mice To Evaluate Frequency of Cytomegalovirus IE1-Derived Peptide Usage in Eliciting Human CD8 Cytokine Response

Gallez-Hawkins

Villacres

et al. 2003

J Virol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Tetramer assay is a well-established way to examine the antigen-specific CTL in mouse models (Villacres et al, 2000; Hovav et al, 2007). Peptide 18 (p18: RGPGRAFVTI) derived from the V3 loop of HIV-1 IIIB gp160 is an epitope recognized by CTL in the BALB/c mouse (H-2D d ) model immunized with HIV-1 IIIB gp160 protein (Takahashi et al, 1988).…”

Section: Methodsmentioning

confidence: 99%

Vaccination with Human Induced Pluripotent Stem Cells Creates an Antigen-Specific Immune Response Against HIV-1 gp160

Amer

2011

Front. Microbio.

View full text Add to dashboard Cite

Induced pluripotent stem cells (iPSCs) are artificially derived from somatic cells that have been transduced with defined reprogramming factors. A previous report has indicated the possibility of using iPSCs as an immune stimulator to generate antigen-specific immunity. In our current study, we have investigated whether human iPSCs (hiPSCs) have the ability to enhance specific immune response against a human immunodeficiency virus type 1 (HIV-1) antigen in a xenogenic mouse model. Our results show that BALB/c mice immunized with hiPSCs transduced with an adenoviral vector encoding HIV-1 gp160 exhibited prominent antigen-specific cellular immune responses. We further found that pre-treatment of hiPSCs with ionizing radiation promotes the secretion of pro-inflammatory cytokines such as interleukin-1 alpha (IL-1α), IL-12, and IL-18. These cytokines might promote the activation of antigen-presenting cells and the effective induction of cellular immunity. Our present findings thus demonstrate that a hiPSCs-based vaccine has the potential to generate cellular immunity against viral antigens such as HIV-1 gp160 in a xenogenic condition.

show abstract

“…SIN-HIV-1Gag immunization of mice elicited CD8 responses, protected mice from vaginal challenge with VVgag [318,327] and maintained long term CD8 T cell memory responses [327]. Both VEE and SIN vectors expressing HIV-1Gag induced antigen-specific CD8 responses in mice when administered alone or in a DNA prime-vector boost regimen.…”

Section: Pre-clinical Studiesmentioning

confidence: 99%

Non-Replicating Viral Vector-Based AIDS Vaccines: Interplay Between Viral Vectors and the Immune System

Sauter

Rahman²,

Muralidhar³

2005

CHR

View full text Add to dashboard Cite

During the past 20 years, the development of HIV vaccines has come a long way. The focus has progressively changed from the traditional protein-based HIV vaccines that induce humoral immunity to the live recombinant viral vector-based HIV vaccines capable of eliciting both cellular and humoral immune responses. These new viral vector-based vaccines encoding multiple HIV antigens, delivered either alone or in heterologous prime-boost modalities elicited antigen-specific CTL responses in immunized hosts and protected animals from disease. The viral vector-based vaccines have proven to be potent vaccines in pre-clinical studies and foster the hope to put an end to the ever-increasing threat of the AIDS epidemic. Several unique features of viral vector-based HIV vaccines have contributed to their success, including their intrinsic immune-modulating properties, high transduction efficiency, and in vivo production of immunogens within the cell mimicking a natural infection without the associated health risks. In this review, we will discuss the characteristics of non-replicating viral vectors most commonly used for HIV vaccines with a particular focus on immune responses elicited by the vector particles alone and their effect on the potency of viral vector-based HIV vaccines.

show abstract

Maintenance of CD8+ T-Cell Memory Following Infection with Recombinant Sindbis and Vaccinia Viruses

Cited by 17 publications

References 59 publications

Use of Transgenic HLA A*0201/Kb and HHD II Mice To Evaluate Frequency of Cytomegalovirus IE1-Derived Peptide Usage in Eliciting Human CD8 Cytokine Response

Use of Transgenic HLA A*0201/Kb and HHD II Mice To Evaluate Frequency of Cytomegalovirus IE1-Derived Peptide Usage in Eliciting Human CD8 Cytokine Response

Vaccination with Human Induced Pluripotent Stem Cells Creates an Antigen-Specific Immune Response Against HIV-1 gp160

Non-Replicating Viral Vector-Based AIDS Vaccines: Interplay Between Viral Vectors and the Immune System

Contact Info

Product

Resources

About